PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model

M. Leduc, B. Grouix, L. Gervais, F. Sarra-Bournet, M. Tremblay, P. Laurin, L. Gagnon (Laval, Canada)

Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?

Session: Cell signalling and inflammation: what's new in 2013?
Session type: Poster Discussion
Number: 4746

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Leduc, B. Grouix, L. Gervais, F. Sarra-Bournet, M. Tremblay, P. Laurin, L. Gagnon (Laval, Canada). PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Eur Respir J 2013; 42: Suppl. 57, 4746

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Targetingpyruvate kinase M2 isoform inhibits proliferation of human lung fibroblasts Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
Bromodomain inhibitor JQ1 attenuates TGF-beta-suppressed SOD2 expression and reduces proliferation in human primary pulmonary fibroblasts Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013
BIBF1120 inhibits fibroblasts proliferation and production of the extracellular matrix protein fibulin-1 Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
A role of Foxc2 gene in mice with bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
Simultaneous inhibition of CTGF and Autotaxin reduces lung fibrosis and improves lung function in mice Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
The enhancement of Stanniocalcin-1 (STC1) secretion increases the ability of mesenchymal stem cells (MSCs) to reduce bleomycin-induced lung fibrosis in a mouse model through inhibition of endoplasmic reticulum stress (ER-stress)/TGFbeta1 pathway Source: International Congress 2014 – ILDs 1 Year: 2014
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
ATF3 regulates PINK1 transcription in lung epithelial cells of the aging lung Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung Year: 2016
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology Source: Eur Respir J 2010; 35: 496-504 Year: 2010
Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Reduction of lung injury and fibrosis by human embrionic stem cells in a mouse model of silica-induced lung fibrosis Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
The effects of tobramycin on pulmonary fibroblast function Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016